Request Deal Involvement
Royalty Pharma completed the acquisition of a 43% of Roche's Risdiplam royalties from PTC Therapeutics for $650m.
Identify your role
Select the side you represented in this transaction, and provide your current job title.
Service Providers
legal advisors
Dechert
or
Principals
bidder
ROYALTY PHARMA
vendor
PTC THERAPEUTICS
target
ROCHE HOLDINGS AG
Principals or Service Provider not listed?Add missing Service Provider or Principal
Enter your Job Title on this deal
This title will appear on your profile next to this deal involvement.
To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:
All rights reserved. Copyright © 2025 Datasite